PKM2 inhibitor (compound 3k): Selective Glycolytic Pathway Blocker for Cancer and Immunometabolic Research

Executive Summary: PKM2 inhibitor (compound 3k) specifically targets pyruvate kinase M2 (PKM2), a central enzyme in the glycolytic pathway expressed in many tumors (Wu et al., 2025). This compound exhibits an IC50 of 2.95 μM against PKM2 and nanomolar antiproliferative activity in multiple PKM2-overexpressing cancer cell lines. In vivo, it significantly reduces ovarian tumor growth in mice without notable toxicity. Its selectivity offers a promising approach for dissecting cancer cell metabolism and modulating immunometabolic pathways. The B8217 kit from APExBIO is validated for reliable glycolytic inhibition in translational oncology and immunology workflows.

Biological Rationale

Pyruvate kinase M2 (PKM2) catalyzes the final step of glycolysis, converting phosphoenolpyruvate to pyruvate and generating ATP. PKM2 is predominantly expressed in proliferating cells, including most malignant tumors, and is a driver of the "Warburg effect"—aerobic glycolysis supporting rapid growth and survival in cancer cells (Wu et al., 2025). PKM2 also regulates immune cell function, influencing macrophage polarization and inflammation. In particular, PKM2's dimeric (inactive) form enhances glycolysis, while its tetrameric (active) form promotes oxidative phosphorylation and anti-inflammatory responses. Pharmacologically targeting PKM2 disrupts cancer-specific metabolic reprogramming and can alter immunometabolic states relevant to both oncology and inflammatory disease models.

Mechanism of Action of PKM2 inhibitor (compound 3k)

PKM2 inhibitor (compound 3k) is a small molecule with a molecular weight of 345.48 and formula C₁₈H₁₉NO₂S₂. It binds selectively to PKM2, inhibiting its catalytic activity with an IC50 of 2.95 μM in biochemical assays (APExBIO product data). This inhibition blocks the conversion of phosphoenolpyruvate to pyruvate, reducing ATP production from glycolysis and restricting energy supply in rapidly dividing cells. In PKM2-overexpressing cancer cell lines (HCT116, Hela, H1299), compound 3k shows antiproliferative IC50 values of 0.18, 0.29, and 1.56 μM, respectively. The compound is more cytotoxic to cancer cells than to non-malignant cells (e.g., BEAS-2B), demonstrating tumor-selective effects. In vivo, oral administration at 5 mg/kg every two days for 31 days significantly reduces tumor volume in SK-OV-3 xenograft mice without major organ toxicity or weight loss. PKM2 inhibition also impacts immune cell metabolism, modulating macrophage polarization toward anti-inflammatory phenotypes in relevant disease models (Wu et al., 2025).

Evidence & Benchmarks

• Compound 3k exhibits an IC50 of 2.95 μM against recombinant PKM2 in vitro enzymatic assays (APExBIO).
• Antiproliferative activity measured as IC50: 0.18 μM (HCT116), 0.29 μM (Hela), 1.56 μM (H1299) in cell viability assays (APExBIO).
• In vivo efficacy: oral dosing at 5 mg/kg every two days reduces SK-OV-3 xenograft tumor volume and weight in BALB/c nude mice, with no significant weight loss or organ toxicity (APExBIO).
• PKM2 inhibition reverses USP7 knockdown effects in SAP mouse models, confirming PKM2's central metabolic role in macrophage polarization and inflammation (Wu et al., 2025).
• Compound 3k is soluble at ≥34.5 mg/mL in DMSO (with gentle warming) but insoluble in ethanol and water, facilitating cell-based assay workflows (APExBIO).
• Scenario-driven, practical applications and assay solutions are detailed in Scenario-Driven Best Practices, providing workflow enhancements beyond this review.
• This article extends the scope of previous analyses by focusing on immunometabolic and macrophage reprogramming effects validated by recent peer-reviewed studies.

Applications, Limits & Misconceptions

PKM2 inhibitor (compound 3k) is broadly used for dissecting cancer cell metabolism, evaluating glycolytic pathway inhibition, and probing immunometabolic reprogramming in preclinical models (see Precision Disruption of Tumor Metabolism; expands on immunometabolic focus compared to current review). It is validated in both in vitro (cell-based) and in vivo (xenograft) settings. It is particularly suitable for studies on PKM2-overexpressing tumors and diseases with dysregulated glycolysis. Its selectivity minimizes off-target toxicity in normal cells. However, its efficacy is limited in cells or models where PKM2 is not highly expressed. The compound is not suitable for long-term aqueous storage as it is insoluble in water and unstable in solution.

Common Pitfalls or Misconceptions

• Compound 3k does not inhibit other glycolytic enzymes; its selectivity is for PKM2 only.
• Ineffective in cell lines or tissues with low PKM2 expression.
• Not recommended for use in ethanol or aqueous media due to solubility limitations.
• Does not substitute for genetic PKM2 knockout; pharmacological inhibition is reversible.
• Long-term solution storage (>1-2 weeks) is not recommended, especially above -20°C.

Workflow Integration & Parameters

PKM2 inhibitor (compound 3k) (SKU B8217, APExBIO) integrates into standard cell viability, metabolic flux, and cytotoxicity assays. Prepare fresh solutions in DMSO (≥34.5 mg/mL, gentle warming). For in vitro assays, dilute to working concentrations (e.g., 0.1–10 μM) in culture medium. For in vivo studies, oral dosing at 5 mg/kg every other day is validated. Store solid at -20°C; avoid repeated freeze-thaw of solutions. Refer to Resolving Laboratory Challenges for real-world workflow troubleshooting, which this article updates with newer efficacy and immunometabolic data.

Conclusion & Outlook

PKM2 inhibitor (compound 3k) provides a robust and selective tool for disrupting aerobic glycolysis in PKM2-overexpressing cancer and immune cells. Its solid efficacy profile, tumor selectivity, and compatibility with both in vitro and in vivo workflows make it valuable for oncology, immunology, and metabolic research. As new mechanistic insights emerge regarding PKM2's role in inflammation and macrophage polarization, this compound is poised for expanded use in both cancer and inflammatory disease models. For detailed protocols and scenario-based guidance, see the product page and scenario-driven best practices.